Internal and Emergency Medicine

, Volume 3, Issue 1, pp 53–56

Rimonabant for overweight and “metabolic syndrome”: the attempt to supersize disease and risk by pharmaceutical marketing

Authors

  • Rita Banzi
    • Italian Cochrane CentreMario Negri Institute for Pharmacological Research
    • Italian Cochrane CentreMario Negri Institute for Pharmacological Research
  • Ivan Moschetti
    • Italian Cochrane CentreMario Negri Institute for Pharmacological Research
  • Alessandro Liberati
    • Italian Cochrane CentreMario Negri Institute for Pharmacological Research
  • Gian Franco Gensini
    • Department of Critical Care Medicine and SurgeryUniversity of Florence and Azienda Ospedaliero-Universitaria Careggi
  • Roberto Gusinu
    • DAI Cardiologico e dei Vasi, Azienda Ospedaliero-Universitaria Careggi
  • Andrea A. Conti
    • Department of Critical Care Medicine and SurgeryUniversity of Florence and Don Carlo Gnocchi Foundation IRCCS
CE - Cochrane's Corner

DOI: 10.1007/s11739-008-0139-x

Cite this article as:
Banzi, R., Moja, L., Moschetti, I. et al. Intern Emerg Med (2008) 3: 53. doi:10.1007/s11739-008-0139-x
  • 60 Views

Copyright information

© SIMI 2008